Leukemias, lymphomas, and other hematologic cancers:

Indications for: ALIQOPA

Treatment of adults with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.

Adult Dosage:

Give as IV infusion over 1hr. 60mg on Days 1, 8, and 15 of a 28-day cycle on an intermittent schedule (3 weeks on, 1 week off). Continue until disease progression or unacceptable toxicity. Moderate hepatic impairment (Child-Pugh B), concomitant strong CYP3A inhibitors: reduce to 45mg. Dose modifications for toxicities: see full labeling.

Children Dosage:

Not established.

ALIQOPA Warnings/Precautions:

Monitor for signs/symptoms of infection (eg, pneumonia); withhold if Grade ≥3 infection develops. Risk of serious pneumocystis jiroveci pneumonia (PJP); consider PJP prophylaxis for those at risks prior to initiation. Diabetes. Obtain optimal blood glucose and blood pressure (BP) control prior to each infusion; monitor closely. Discontinue if blood glucose ≥500mg/dL is persistent at Copanlisib 30mg dose. Discontinue if post-dose BP remains uncontrolled (>150/90mmHg) despite antihypertensives or elevated with life-threatening consequences. Withhold and treat if non-infectious pneumonitis occurs; discontinue if Grade 2 recurs or if Grade ≥3 develops. Monitor ANC at least weekly; withhold if ANC <0.5 x 103 cells/mm3; reduce to 45mg if ANC ≤0.5 x 103 cells/mm3 recurs. Monitor for severe cutaneous reactions; withhold for Grade 3 reaction; discontinue if life-threatening. Monitor for thrombocytopenia, other severe and non-life-threatening toxicities; see full labeling. Severe hepatic impairment: not studied. Embryo-fetal toxicity. Advise females of reproductive potential and males (w. female partners) to use highly effective contraception during treatment and for ≥1 month after last dose. Pregnancy; exclude status prior to initiation. Nursing mothers: not recommended (during and for ≥1 month after last dose).

ALIQOPA Classification:

Kinase inhibitor.

ALIQOPA Interactions:

May be antagonized by strong CYP3A inducers (eg, rifampin, St. John’s wort); avoid. Potentiated by strong CYP3A inhibitors (eg, itraconazole, grapefruit juice); if concomitant use unavoidable, reduce Copanlisib dose (see Adults).

Adverse Reactions:

Hyperglycemica, diarrhea, decreased general strength/energy, hypertension, leukopenia, neutropenia, nausea, lower respiratory tract infections, thrombocytopenia.

Generic Drug Availability:


How Supplied:

Single-dose vial—1

Pricing for ALIQOPA

60mg vial (Qty: 1)
Appx. price $4960